{"id":10959,"date":"2023-12-04T00:38:00","date_gmt":"2023-12-03T16:38:00","guid":{"rendered":"https:\/\/flcube.com\/?p=10959"},"modified":"2024-11-03T00:41:01","modified_gmt":"2024-11-02T16:41:01","slug":"nona-biosciences-partners-with-lycia-therapeutics-to-advance-lytac-platform-for-novel-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10959","title":{"rendered":"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies"},"content":{"rendered":"\n

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142<\/a>), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona’s proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for challenging, unspecified diseases. Financial terms of the agreement remain undisclosed.<\/p>\n\n\n\n

Lycia intends to utilize Nona\u2019s Harbour Mich HCAb fully human antibody transgenic mice platform to identify novel antibodies for its LYTAC protein degrader therapeutics. Nona\u2019s LYTAC technology enables the creation of drugs that effectively address extracellular disease-driving targets, which are often difficult to tackle using traditional antibody and small molecule approaches.- Flcube.com<\/a> <\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[129,916,1858,128,70],"class_list":["post-10959","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hbm-holdings","tag-hkg-2142","tag-lycia-therapeutics","tag-nona-biosciences","tag-tpd"],"yoast_head":"\nNona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona's proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for challenging, unspecified diseases. Financial terms of the agreement remain undisclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10959\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10959\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-03T16:38:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-02T16:41:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10959#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10959\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies\",\"datePublished\":\"2023-12-03T16:38:00+00:00\",\"dateModified\":\"2024-11-02T16:41:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10959\"},\"wordCount\":131,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HBM Holdings\",\"HKG: 2142\",\"Lycia Therapeutics\",\"Nona Biosciences\",\"TPD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10959#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10959\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10959\",\"name\":\"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-12-03T16:38:00+00:00\",\"dateModified\":\"2024-11-02T16:41:01+00:00\",\"description\":\"Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona's proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for challenging, unspecified diseases. Financial terms of the agreement remain undisclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10959#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10959\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10959#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies - Insight, China's Pharmaceutical Industry","description":"Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona's proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for challenging, unspecified diseases. Financial terms of the agreement remain undisclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10959","og_locale":"en_US","og_type":"article","og_title":"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10959","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-12-03T16:38:00+00:00","article_modified_time":"2024-11-02T16:41:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10959#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10959"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies","datePublished":"2023-12-03T16:38:00+00:00","dateModified":"2024-11-02T16:41:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10959"},"wordCount":131,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HBM Holdings","HKG: 2142","Lycia Therapeutics","Nona Biosciences","TPD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10959#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10959","url":"https:\/\/flcube.com\/?p=10959","name":"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-12-03T16:38:00+00:00","dateModified":"2024-11-02T16:41:01+00:00","description":"Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona's proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for challenging, unspecified diseases. Financial terms of the agreement remain undisclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10959#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10959"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10959#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10959"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10959\/revisions"}],"predecessor-version":[{"id":10961,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10959\/revisions\/10961"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}